Swiss Biotech Stock News

Novartis (SWX:NOVN) agreed to acquire Excellergy, a biotech focused on anti IgE therapies for allergic diseases, including food allergies. The company reported positive final two year Phase III results for Fabhalta in IgA nephropathy, indicating slower kidney function decline in the study population. The FDA granted Fabhalta priority review for traditional approval in IgA nephropathy. For investors watching large pharma, Novartis sits at the intersection of immunology, allergy, and kidney...

The recent U.S. District Court order upholding a jury finding that Alcon (SWX:ALC) willfully infringed three Sight Sciences patents puts fresh attention on potential legal liabilities, ongoing Hydrus Microstent royalties, and appeal risk. See our latest analysis for Alcon. At a share price of CHF59.4, Alcon has a 1 day share price return of 0.58% and a 7 day share price return of 1.85%. However, a 1 year total shareholder return of 28.37% decline shows sentiment has cooled despite earlier...

PolyPeptide Group (SWX:PPGN) has expanded its credit facility to €200 million, bringing ING Bank into its lending group alongside UBS, Danske Bank and Zürcher Kantonalbank to support its revenue and capacity expansion objectives. See our latest analysis for PolyPeptide Group. That credit facility news arrives as momentum has been picking up, with the 7 day share price return of 8.54% and year to date share price return of 11.25% feeding into a 1 year total shareholder return of 62.61%. The...

If you are wondering whether UBS Group's current share price reflects its true value, focusing on what the numbers say rather than the headlines can help clarify the picture. The stock recently closed at CHF 29.38, with returns of 12.9% over 1 year and 70.6% over 3 years, alongside a 23.0% decline year to date and an 8.2% decline over the last 30 days. These moves may signal shifting expectations or risk perceptions. Recent coverage around UBS Group has highlighted its role as a global...

Wondering whether Nestlé at around CHF 76.37 is priced for quality, or leaving some value on the table for patient shareholders? The stock is up 0.7% over the last week, while the 30 day return is a 9.1% decline and the one year return is a 12.3% decline, which may change how you think about both upside and risk. Recent coverage has focused on Nestlé's position as a global consumer staples giant, its broad portfolio of food and beverage brands, and how that scale influences investor...

Why Roche Holding (SWX:ROG) is in Focus After Its New Respiratory Test Launch Roche Holding (SWX:ROG) is back on investors radar after unveiling its cobas eplex respiratory pathogen panel 3, a multiplex test aimed at quickly identifying a wide range of respiratory viruses and bacteria from a single sample. See our latest analysis for Roche Holding. The new respiratory panel lands at a time when Roche Holding’s 1-month share price return of 10.47% decline contrasts with a 10.30% 1-year total...

Implenia AG ( VTX:IMPN ) stock is about to trade ex-dividend in three days. Typically, the ex-dividend date is two...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Recent share performance snapshot Sandoz Group (SWX:SDZ) has seen a mix of short term pressure and longer term strength, with a 0.3% decline over the past day, 0.5% over the past week and 16.5% over the past month, but a 3.2% gain over the past 3 months and a 62.6% total return over the past year. See our latest analysis for Sandoz Group. The recent 30 day share price return of 16.5% contrasts with a 62.6% total shareholder return over the past year. This suggests that earlier gains have...

Why Amrize Stock Is On Investors’ Radar Amrize (SWX:AMRZ) has drawn fresh attention after a recent share price pullback, with the stock showing a 12.7% decline over the past month and a 1.1% slip over the past 3 months. See our latest analysis for Amrize. The recent 12.7% 1 month share price return decline comes after a relatively mild 2.7% negative share price return year to date. This suggests that momentum has cooled rather than strengthened in the short term. If this pullback has you...

Edisun Power Europe (SWX:ESUN) has put out a mixed set of FY 2025 numbers, with first half revenue at CHF7.2 million and a basic EPS loss of CHF2.73, against a trailing twelve month picture that shows revenue of CHF50.9 million and basic EPS of CHF1.06. Over recent periods, revenue has moved between CHF7.8 million in 1H 2024 and CHF43.7 million in 2H 2024, while EPS has swung from a loss of CHF1.21 in 1H 2024 to EPS of CHF3.96 in 2H 2024, underlining just how volatile profitability has been...

GAM Holding (SWX:GAM) has put fresh numbers on the table for FY 2025, with first half revenue of CHF 25.7 million and basic EPS of CHF 0.038 loss per share, while trailing 12 month figures to the same point show revenue of CHF 62.5 million and a basic EPS loss of CHF 0.100897. Over the past three reported halves, revenue has moved from CHF 43.9 million in 1H 2024 to CHF 37.7 million in 2H 2024 and then to CHF 25.7 million in 1H 2025, alongside basic EPS losses of CHF 0.248253, CHF 0.08653 and...

Nestlé is advancing the sale of its stake in its waters business, with private equity bidders moving forward in the process. The potential transaction is part of a broader effort to reshape the portfolio toward core areas such as coffee, pet food, nutrition, and food. The outcome of the bidding could influence how Nestlé allocates capital and manages its mix of brands in the coming years. For investors following SWX:NESN, this potential sale comes as the share price stands at CHF76.37, with...

Latest FY 2025 earnings snapshot Vaudoise Assurances Holding (SWX:VAHN) has just posted its FY 2025 numbers with first half revenue of CHF 777.1 million, basic EPS of CHF 28.89 and net income of CHF 84.1 million, alongside a combined ratio of 96.7%. Trailing 12 month figures show revenue of about CHF 1.5 billion, EPS of CHF 51.65 and net income of CHF 149.9 million. Over recent periods, revenue has moved from CHF 779.7 million in the first half of 2024 to CHF 777.1 million in the first half...

UBS Global Wealth Management has adjusted its global asset allocation to a more defensive stance in response to ongoing geopolitical tensions, including the Iran conflict. The firm has shifted its regional views, moving India and the euro zone to neutral while upgrading Switzerland and European healthcare. These changes affect how UBS positions client portfolios in energy sensitive and risk exposed markets. For investors tracking UBS Group (SWX:UBSG), the latest positioning changes at its...

As you might know, Newron Pharmaceuticals S.p.A. ( VTX:NWRN ) recently reported its annual numbers. It was a moderately...

Dividend and guidance draw attention to Medacta Group Medacta Group (SWX:MOVE) has attracted fresh investor interest after announcing an annual dividend of CHF 1.10 per share and issuing 2026 revenue growth guidance in a 10% to 14% range in constant currency. See our latest analysis for Medacta Group. The stock’s 1-day share price return of 1.62% contrasts with a weaker year-to-date share price return showing a 5.05% decline, while the 1-year total shareholder return of 14.85% points to...

In March 2026, Logitech International announced a new three-year share repurchase program of up to US$1.40 billion, alongside leadership changes and, on March 17, the global launch of the Logitech G RS H‑Shifter for sim racing enthusiasts. Together, the sizeable buyback authorization and expansion of Logitech’s high-end racing ecosystem highlight management’s focus on capital return and deepening engagement with committed gaming users. We’ll now examine how the US$1.40 billion share...

As European markets navigate heightened geopolitical tensions and soaring energy costs, investors are increasingly focused on the potential impact of these factors on inflation and economic stability. In this uncertain environment, dividend stocks may offer a measure of resilience by providing regular income streams that can help cushion against market volatility.

As European markets navigate the challenges of heightened energy prices and geopolitical tensions, investors are increasingly focused on companies that demonstrate resilience and potential for growth. In such uncertain times, stocks with high insider ownership can signal strong confidence from those who know the business best, making them attractive candidates for consideration in a volatile market environment.

Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...

As European markets navigate heightened uncertainty stemming from geopolitical tensions and rising energy costs, investors are increasingly focusing on companies with strong fundamentals and insider confidence. In this environment, growth stocks with substantial insider ownership can offer a unique perspective on potential resilience and alignment of interests between management and shareholders.

Stadler Rail AG's ( VTX:SRAIL ) stock was strong after they recently reported robust earnings. We did some analysis and...

Investis Holding SA's ( VTX:IREN ) recent weak earnings report didn't cause a big stock movement. However, we believe...